Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV

Pediatrics

Volumn 111, Issue 5 I, 2003, Pages 1030-1036

  Zeitlin, Leonid ^b   Rauch, Frank ^b   Plotkin, Horacio ^b   Glorieux, Francis H ^a  

^a SHRINERS HOSPITAL FOR CHILDREN   (Canada)

^b NONE

Author keywords

Bisphosphonates; Child and adolescent; Growth; Osteogenesis imperfecta; Pamidronate

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID;

ADOLESCENT; ARTICLE; BODY HEIGHT; BODY WEIGHT; BONE DENSITY; BONE MINERAL; BONE PAIN; CHILD; CHILD GROWTH; CLINICAL TRIAL; FEMALE; FRACTURE; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; OSTEOGENESIS IMPERFECTA; PRIORITY JOURNAL; SPINE RADIOGRAPHY; TREATMENT OUTCOME;

ADOLESCENT; AGING; BODY HEIGHT; BODY WEIGHT; BONE AND BONES; BONE DENSITY; CHILD; CHILD DEVELOPMENT; CHILD, PRESCHOOL; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INJECTIONS, INTRAVENOUS; MALE; OSTEOGENESIS IMPERFECTA; TIBIA;

EID: 0013409162     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.111.5.1030     Document Type: Article

References (24)

1. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16:101-116
2. Brumsen C, Hamdy NA, Papapoulos SE. Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis. Medicine. 1997;76:266-283
3. Bembi B, Parma A, Bottega M, et al. Intravenous pamidronate treatment in osteogenesis imperfecta. J Pediatr. 1997;131:622-625
4. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998;339:947-952
5. Plotkin H, Rauch F, Bishop NJ, et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab. 2000;85:1846-1850
6. Lee YS, Low SL, Lim LA, Loke KY. Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta. Eur J Pediatr. 2001;160:641-644
7. Astrom E, Soderhall S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child. 2002;86:356-364
8. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998;19:80-100
9. Srivastava T, Alon US. Bisphosphonates: from grandparents to grandchildren. Clin Pediatr. 1999;38:687-702
10. Baron RE. Anatomy and ultrastructure of bone. In: Favus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 4th ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 1999:3-10
11. Miller SC, Jee WS, Woodbury DM, Kemp JW. Effects of N,N,N′,N′-ethylenediaminetetramethylene phosphonic acid and 1-hydroxyethylidene-1,1-bisphosphonic acid on calcium absorption, plasma calcium, longitudinal bone growth, and bone histology in the growing rat. Toxicol Appl Pharrnacol. 1985;77:230-239
12. Schenk R, Eggli P, Fleisch H, Rosini S. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int. 1986;38:342-349
13. Pataki A, Muller K, Green JR, Ma YF, Li QN, Jee WS. Effects of short-term treatment with the bisphosphonates zoledronate and pamidronate on rat bone: a comparative histomorphometric study on the cancellous bone formed before, during, and after treatment. Anat Rec. 1997;249:458-468
14. Lepola VT, Hannuniemi R, Kippo K, Lauren L, Jalovaara P, Vaananen HK. Long-term effects of clodronate on growing rat bone. Bone. 1996; 18:191-196
15. Landsmeer-Beker EA, Massa GG, Maaswinkel-Mooy PD, van de Kamp JJ, Papapoulos SE. Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate). Eur J Pediatr. 1997;156:792-794
16. Glorieux FH, Rauch F, Plotkin H, et al. Type V osteogenesis imperfecta: a new form of brittle bone disease. J Bone Miner Res. 2000;15:1650-1658
17. Glorieux FH, Ward LM, Rauch F, Lalic L, Roughley PJ, Travers R. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J Bone Miner Res. 2002;17:30-38
18. Ward LM, Rauch F, Travers R, et al. Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. Bone. 2002;31:12-18
19. Greulich WW, Pyle SI. Radiographic Atlas of Skeletal Development of the Hand and Wrist. 2nd ed. Stanford, CA: Stanford University Press; 1959
20. Hamill PV, Drizd TA, Johnson CL, Reed RB, Roche AF, Moore WM. Physical growth: National Center for Health Statistics percentiles. Am J Clin Nutr. 1979;32:607-629
21. Luhmann SJ, Sheridan JJ, Capelli AM, Schoenecker PL. Management of lower-extremity deformities in osteogenesis imperfecta with extensible intramedullary rod technique: a 20-year experience. J Pediatr Orthop. 1998;18:88-94
22. Vetter U, Pontz B, Zauner E, Brenner RE, Spranger J. Osteogenesis imperfecta: a clinical study of the first ten years of life. Calcif Tissue Int. 1992;50:36-41
23. Rowe DW, Shapiro JR. Osteogenesis imperfecta. In: Avioli LV, Krane SM, eds. Metabolic Bone Disease and Clinically Related Disorders. 3rd ed. San Diego, CA: Academic Press; 1998:651-695
24. Cropp GJ, Myers DN. Physiological evidence of hypermetabolism in osteogenesis imperfecta. Pediatrics. 1972;49:375-391